Compare DXLG & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DXLG | ACET |
|---|---|---|
| Founded | 1976 | 1947 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.6M | 93.5M |
| IPO Year | 1987 | N/A |
| Metric | DXLG | ACET |
|---|---|---|
| Price | $1.10 | $0.54 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 4 |
| Target Price | $2.50 | ★ $8.50 |
| AVG Volume (30 Days) | 75.7K | ★ 1.9M |
| Earning Date | 12-11-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $447,744,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.95 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.88 | $0.45 |
| 52 Week High | $3.10 | $1.12 |
| Indicator | DXLG | ACET |
|---|---|---|
| Relative Strength Index (RSI) | 59.75 | 35.12 |
| Support Level | $1.01 | $0.50 |
| Resistance Level | $1.23 | $0.57 |
| Average True Range (ATR) | 0.08 | 0.05 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 62.86 | 18.38 |
Destination XL Group Inc is a retailer of branded and Tall men's clothing and shoes in the United States. It also sells products across the world. The company sells its products under the trade names Destination XL, DXL, DXL Men's Apparel, DXL outlets, Casual Male XL, and Casual Male XL outlets. The company has two principal operating segments: Store, and Direct business.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.